Keywords: Alzheimer's Disease, Quantitative Susceptibility mapping, CMB, 2D GRE, mcTFI, Anti-amyloid therapyCerebral microbleeds/microhemorrhages (CMB) are used for risk stratification, including for the hemorrhagic complication ARIA-H of Alzheimer’s anti-amyloid therapy. For AD, risk information is based on many trials using 2DGRE technique, which is MRI field and parameter dependent. The use of techniques that better distinguish CMB mimics, like calcifications, is limited by an unclear relationship to 2D GRE CMB depiction. In this study we found the number of CMB candidate lesions between 2D GRE and mcTFI QSM obtained during the same scan session highly correlated, suggesting mcTFI could be used in the management of pathologies evaluating presence and number of CMBs.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords